The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity ...
The combination of diet, exercise and GLP-1 therapies enhances weight loss, improves body composition, reduces visceral fat and inflammation, and may confer longer-term benefits in slowing weight regain.
Glucagonlike peptide1 receptor agonists (GLP1Ras) are widely used to treat type 2 diabetes. They not only reduce glucose, but also have a positive effect on weight loss. However, few studies have reported the effect of GLP1Ras on fat distribution.
Patients with obesity on GLP-1 medicines improve their body composition without negatively affecting strength. Overall, in middle-aged mice and men, GLP-1 medicines slightly decrease absolute muscle values but positively impact body composition and mobility.
Decline in oestrogen levels: As oestrogen levels decline, there is a corresponding increase in body fat distribution, particularly around the abdomen. This shift is partly due to the loss of oestrogen's protective effects against fat accumulation in the abdominal area.
:max_bytes(150000):strip_icc()/HDC-GettyImages-2195485788-299e147644524b339a084114355dff83.jpg "Image result for glp 1 and improved body fat distribution improvement")
